Discovery of CDK8/19 inhibitors as lead compounds for IL-6–dependent lymphoma enabled by the formal synthesis of cortistatin A
Science Advances · 2026
DOI: 10.1126/sciadv.aeg8852 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Wenjun Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Physiology, Shenzhen Bay Laboratory, Shenzhen, Guangdong 518055, China. Hauptthemen laut MEDLINE: Interleukin-6, Cyclin-Dependent Kinase 8, Protein Kinase Inhibitors, Cyclin-Dependent Kinases. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Peking-Tsinghua Center for Life sciences.
Abstract (Originalsprache)
A formal synthesis of cortistatin A, a marine-derived steroidal alkaloid with potent anti-angiogenic and antileukemic activities, was achieved via a unique synthetic strategy that leveraged a late-stage SmI 2 -mediated oxa-bridge translocation. The de novo–synthesized simplified analog CA411 was evaluated across 38 cell lines, revealing potent and selective antiproliferative activity against a diffuse large B cell lymphoma (DLBCL) line OCI-Ly3. Time-course transcriptomics and mechanistic studies demonstrated that it disrupts an autocrine IL-6–JAK2–STAT3 signaling loop, reducing IL-6 secretion, STAT3 phosphorylation, and downstream anti-apoptotic genes, thereby inducing apoptosis. Not only this selectivity extends to other CDK8/19 inhibitors and IL-6–dependent models, but CA411 also suppressed OCI-Ly3 xenograft growth, diminished IL-6 expression, induced anti-angiogenic effects with vascular normalization, and prolonged survival in mouse models. These findings position CDK8/19 inhibitors like cortistatins as leads for IL-6–dependent lymphomas, highlighting a targetable vulnerability in cytokine-driven malignancies and bridging synthetic innovation with therapeutic discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Molecular Physiology, Shenzhen Bay Laboratory, Shenzhen, Guangdong 518055, China.
- Institute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, Guangdong 518055, China.
- Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China.
- Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, Beijing National Laboratory for Molecular Science, College of Chemistry and Molecular Engineering, Peking University, Beijing 10…
ORCID-Profile: Wenjun Wang, Nan Zhang, Guihua Zeng, Tuoping Luo
Förderung
- National Natural Science Foundation of China
- Peking-Tsinghua Center for Life sciences
Zitieren
APA
Wang, W., Zhang, N., Chen, B., Chen, Z., Zeng, G., & Luo, T. (2026). Discovery of CDK8/19 inhibitors as lead compounds for IL-6–dependent lymphoma enabled by the formal synthesis of cortistatin A. Science Advances. https://doi.org/10.1126/sciadv.aeg8852
Vancouver
Wang W, Zhang N, Chen B, Chen Z, Zeng G, Luo T. Discovery of CDK8/19 inhibitors as lead compounds for IL-6–dependent lymphoma enabled by the formal synthesis of cortistatin A. Science Advances. 2026. doi:10.1126/sciadv.aeg8852
BibTeX
@article{Wang2026,
author = {Wang, Wenjun and Zhang, Nan and Chen, Baicheng and Chen, Zijing and Zeng, Guihua and Luo, Tuoping},
title = {Discovery of CDK8/19 inhibitors as lead compounds for IL-6–dependent lymphoma enabled by the formal synthesis of cortistatin A},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aeg8852}
}
EUVIMED